Dr Reddy's Laboratories Announces Launch of Bivalirudin for Injection in US Market
Hyderabad & Princeton: Dr. Reddy’s Laboratories Ltd. announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax® (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health.
Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.
Angiomax® is a registered trademark of The Medicines Company.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd